India's CDSCO flags 25 drugs as not of standard quality

12 June 2020

India's apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO) has flagged 25 drug batches for failing to qualify in a random drug sample test.

The drug samples include doxepin hydrochloride capsules by Intas Pharma, levetiracetam injection by SBS Biotech, nifedipine capsules by Torrent Pharma (BSE: 500420), and several others that were declared as 'Not of Standard Quality' (NSQ).

An analysis was conducted by the CDSCO and Drug Control Departments on 477 drug samples. Of these, 452 samples were found of standard quality while 25 were declared as NSQ/ spurious/ adulterated/ misbranded, for the Month of May 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK